News for Regeneron Pharmaceuticals, Inc. (0R2M.L)

In the current session, Regeneron Pharmaceuticals Inc. REGN is trading at $672.39, after a 0.89% decrease. Over the past month, the stock decreased by 0.97%, an...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for more on REGN stock news.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ETCompany ParticipantsRyan...

We recently compiled a list of the 11 Oversold Blue Chip Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals,

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 10, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Fir

LOS ANGELES, March 10, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of sha

PR NewswireNEW YORK, March 10, 2025 NEW YORK, March 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Ph

PR NewswireLOS ANGELES, March 10, 2025 LOS ANGELES, March 10, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, remi

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Regeneron

**media[560956]**

**media[560955]**

Regeneron Pharmaceuticals Inc (REGN) and Sanofi have announced positive results from their ADEPT Phase 2/3 trial, evaluating Dupixent® (dupilumab) for treating

PR NewswireNEW YORK, March 7, 2025 NEW YORK, March 7, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securit

[url="]The Law Offices of Frank R. Cruz[/url] reminds investors of the upcoming March 10, 2025 deadline to participate as a lead plaintiff in the securities fr

PR NewswireLOS ANGELES, March 7, 2025 LOS ANGELES, March 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, remind